<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJRA</journal-id><journal-title-group><journal-title>Open Journal of Rheumatology and Autoimmune Diseases</journal-title></journal-title-group><issn pub-type="epub">2163-9914</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojra.2020.101001</article-id><article-id pub-id-type="publisher-id">OJRA-96927</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Etiologies of Bone Metastases at the Rheumatology Department (UTH) of Abidjan
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mariam</surname><given-names>Gbané</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean</surname><given-names>Claude Soglo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mohamed</surname><given-names>Diomandé</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Guy</surname><given-names>Léopold Kengni</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Baly</surname><given-names>Ouattara</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jean</surname><given-names>Mermoz Djaha Kouassi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>You</surname><given-names>Nina Carmelle Kpami</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yaya</surname><given-names>Coulibaly</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Edmond</surname><given-names>Eti</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Rheumatology Department, University Teaching Hospital (UTH) of Cocody, Abidjan, C&amp;amp;#244;te d'Ivoire</addr-line></aff><pub-date pub-type="epub"><day>06</day><month>12</month><year>2019</year></pub-date><volume>10</volume><issue>01</issue><fpage>1</fpage><lpage>7</lpage><history><date date-type="received"><day>22,</day>	<month>October</month>	<year>2019</year></date><date date-type="rev-recd"><day>3,</day>	<month>December</month>	<year>2019</year>	</date><date date-type="accepted"><day>6,</day>	<month>December</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Objectives: The aim of this study was to describe the diagnostic and etiological aspects of bone metastases in the Rheumatology Department of Cocody’s University Teaching Hospital (UTH). 
  Methodology: This was a descriptive, 11-year retrospective study (January 1, 2006 to December 31, 2016) of inpatient records of bone metastases. The diagnosis was made on clinical (bone signs), radiological (osteolysis, bone condensation) and sometimes histological basis. 
  Result: Eighty out of 6, 1111 inpatients suffered from bone metastasis with a hospital frequency of 1.30%. The average age was 60.74 years (range 26 to 81 years). Men were predominant (53 men for 27 women) with a sex ratio of 1.96. The main complaints were pain (97.6%). chronic (90%), severe (73.8%), inflammatory (93.8%). There was sometimes a neurological complication: a motor deficit (21.3%), sensitive (13.8%). These symptoms were associated with fever (56.3%) and altered general state (85%). Bone metastases have been revealing in the vast majority of cases (93.75%); the primary cancer was known only in 5 patients (prostate = 2, breast = 2 and cervix = 1). Bone condensation (61.3%), osteolysis (50%) and mixed lesions (7.5%) where the main radiological lesions observed. The primary tumors were: prostatic (50%), pulmonary (18.8%), mammary (11.3%), uterine (5%), renal (2.5%), hepatic (2.5%), bladder (1.3%) and adrenal (1.3%). 
  Conclusion: Bone metastases affect mostly the elderly; inflammatory spinal pain is the main symptom. Bone condensation is the most common radiologic lesion. The prostate, breast and lungs are the main primary tumors.
 
</p></abstract><kwd-group><kwd>Bone Metastases</kwd><kwd> Bone Condensation</kwd><kwd> Prostate Cancer</kwd><kwd> Africa</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Bone is the third metastatic localization after the lung and liver [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>].</p><p>It is a frequent location of metastases in many cancers, particularly during prostate, breast and lung cancer [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>].</p><p>Their occurrence is associated with significant morbidity, decreased quality of life and survival. It is therefore important to make an early diagnosis for optimal management [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref2">2</xref>].</p><p>In sub-Saharan Africa, many studies concerning bone metastases have been published, particularly in Ivoiry Coast: Kouakou [<xref ref-type="bibr" rid="scirp.96927-ref3">3</xref>] ; Daboiko [<xref ref-type="bibr" rid="scirp.96927-ref4">4</xref>] ; Konan [<xref ref-type="bibr" rid="scirp.96927-ref5">5</xref>] ; in Congo: Brazzaville: Bileckot [<xref ref-type="bibr" rid="scirp.96927-ref6">6</xref>], and in Togo: Oniankitan [<xref ref-type="bibr" rid="scirp.96927-ref7">7</xref>]. The last study in the rheumatology department concerning bone metastases (BM) dates back to 2002. She concluded that: prostate cancer was the most common etiology the objective was to describe the bone metastasis diagnostic arguments and to identify the etiologies of bone metastases in the rheumatology department of Cocody’s UTH.</p></sec><sec id="s2"><title>2. Materials and Method</title><p>This was a retrospective descriptive study on files from January 1, 2005 to December 31, 2016 in the rheumatology department of Cocody’s University Teaching Hospital. It included all patients admitted to hospital for a secondary bone tumor. The diagnosis is based on signs, symptoms and imaging. It was clinically based on bone signs (bone pain, bone swelling, pathological fracture), neurological complications, deterioration of the general state, radiological signs (osteolysis, bone condenstaion); biological tests and as possible on the histology. This data was processed with the SPSS 18.0 and the entry was made on Word 2013.</p></sec><sec id="s3"><title>3. Results</title><p>Six thousand one hundred and eleven patients were hospitalized from January 1st, 2005 to December 31st, 2016 in the Rheumatology department of Cocody’s UTH, of whom 80 had secondary bone tumors. The hospital frequency was 01.30%. There were 53 men (66.25%) and 27 women (33.75%) with a sex ratio of 1.96. The average age was 60.74 years with extremes of 26 and 81 years.</p><p>Bone metastases have been revealing in the vast majority of cases (93.75%); the primary cancer was known only in 5 patients (prostate = 2, breast = 2 and cervix = 1).</p><p>The main complaint was bone pain (97.5%). Pain was chronic (90.0%); progressive (92.5%), inflammatory (93.8%) and severe (73.8%). Other signs were bone swelling (12.5%) and pathological fractures (08.8%).</p><p>The spine was the most common seat of pain with a clear predominance for the lumbar segment (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The neurological complications were: motor deficit (21.3%), genital sphinter disorders (21.3%) and sensitive deficit (13.8%). These symptoms were associated with fever (56.3%) and an altered general state (85%).</p><p>Radiographic lesions of bone metastases are listed in <xref ref-type="table" rid="table2">Table 2</xref>. Bone condensation was the most frequent radiological lesion of bone metastases (61.3%).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Seat of pain</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Seat of pain</th><th align="center" valign="middle" >Number (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle"  colspan="2"  >Skull</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2.5</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Spine</td><td align="center" valign="middle" >Cervical</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.0</td></tr><tr><td align="center" valign="middle" >Dorsal</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >36.3</td></tr><tr><td align="center" valign="middle" >Lombosacral</td><td align="center" valign="middle" >70</td><td align="center" valign="middle" >87.6</td></tr><tr><td align="center" valign="middle"  rowspan="3"  >Upper limbs</td><td align="center" valign="middle" >Shoulders</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15</td></tr><tr><td align="center" valign="middle" >Forearm</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >12.6</td></tr><tr><td align="center" valign="middle" >Elbows</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle"  rowspan="5"  >Lower limbs</td><td align="center" valign="middle" >Tights</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >18.8</td></tr><tr><td align="center" valign="middle" >Pelvis</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >20</td></tr><tr><td align="center" valign="middle" >Knees</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >15.1</td></tr><tr><td align="center" valign="middle" >Legs</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.6</td></tr><tr><td align="center" valign="middle" >Ankles</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >6.3</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Radiological lesions of bone metastases</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Standard x-ray pictures</th><th align="center" valign="middle" >Number (n)</th><th align="center" valign="middle" >Percentage (%)</th></tr></thead><tr><td align="center" valign="middle" >Osteolysis</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >25.0</td></tr><tr><td align="center" valign="middle" >Vertebral compression</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >25.0</td></tr><tr><td align="center" valign="middle" >Bone condensations</td><td align="center" valign="middle" >49</td><td align="center" valign="middle" >61.3</td></tr><tr><td align="center" valign="middle" >Mixed pictures</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >7.5</td></tr></tbody></table></table-wrap><p>Tumor markers were found in 42 patients (52.6%) and distributed as follows:</p><p>PSA (n = 38), CA 15-3 (n = 3), alpha fetoprotein (n = 1).</p><p>Ultrasound was contributive to investigate for the primary tumor in the most of cases (75.1%).</p><p>Tumor biopsy for histological examination was performed in only 14 patients (11.5%) and confirmed prostate adenocarcinoma in 6 patients, ductal carcinoma of the breast in 4 patients, adenocarcinoma of the breast in 2 patients, adenocarcinoma of thyroid in 2 patients.</p><p>The main etiologies of bone metastases found in the rheumatology department; have been listed in <xref ref-type="table" rid="table3">Table 3</xref>.</p><p>Prostate cancer remains the most common etiology according these 3 studies.</p><p>The characteristics of the main primary tumors have been described in <xref ref-type="table" rid="table4">Table 4</xref>.</p></sec><sec id="s4"><title>4. Discussion</title><p>The main limitation of this study which is the absence of histology for all patients.</p><p>In term of epidemiology and clinic, our results generally meet those of many studies founded in literature, specially:</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Etiology of bone metastases</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Primitive tumors</th><th align="center" valign="middle" >Kouakou 26 cases (1988-1990)</th><th align="center" valign="middle" >Daboiko 42 cases (1994-2002)</th><th align="center" valign="middle" >Our study 80 cases (2005-2016)</th></tr></thead><tr><td align="center" valign="middle" >Prostatic</td><td align="center" valign="middle" >34.61</td><td align="center" valign="middle" >54.8%</td><td align="center" valign="middle" >50%</td></tr><tr><td align="center" valign="middle" >Pulmonary</td><td align="center" valign="middle" >7.69</td><td align="center" valign="middle" >2.4%</td><td align="center" valign="middle" >18.8%</td></tr><tr><td align="center" valign="middle" >Breast</td><td align="center" valign="middle" >3.85</td><td align="center" valign="middle" >2.4%</td><td align="center" valign="middle" >11.3%</td></tr><tr><td align="center" valign="middle" >Thyroid</td><td align="center" valign="middle" >7.69</td><td align="center" valign="middle" >7.1%</td><td align="center" valign="middle" >7.5%</td></tr><tr><td align="center" valign="middle" >Uterine</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.5%</td></tr><tr><td align="center" valign="middle" >Cervix</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.5%</td></tr><tr><td align="center" valign="middle" >Renal</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.5%</td></tr><tr><td align="center" valign="middle" >Liver</td><td align="center" valign="middle" >11.54</td><td align="center" valign="middle" >7.1%</td><td align="center" valign="middle" >2.5%</td></tr><tr><td align="center" valign="middle" >Bladder</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.3%</td></tr><tr><td align="center" valign="middle" >Adrenal</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.3%</td></tr><tr><td align="center" valign="middle" >Colon</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.4%</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Ovary</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >4.8%</td><td align="center" valign="middle" >-</td></tr><tr><td align="center" valign="middle" >Unknown</td><td align="center" valign="middle" >13.06</td><td align="center" valign="middle" >19%</td><td align="center" valign="middle" >Excluded</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Characteristics of primary tumors</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >Prostate (n = 40)</th><th align="center" valign="middle" >Lungs (n = 15)</th><th align="center" valign="middle" >Breast (n = 9)</th><th align="center" valign="middle" >Thyro&#239;d (n = 6)</th><th align="center" valign="middle" >Uterus (n = 4)</th><th align="center" valign="middle" >Liver (n = 2)</th></tr></thead><tr><td align="center" valign="middle" >Sex</td><td align="center" valign="middle" >M</td><td align="center" valign="middle" >8 M: 7 F</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >5 F: 1 M</td><td align="center" valign="middle" >F</td><td align="center" valign="middle" >M</td></tr><tr><td align="center" valign="middle" >Average age (years)</td><td align="center" valign="middle" >62,5</td><td align="center" valign="middle" >56</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >62,5</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >48</td></tr><tr><td align="center" valign="middle" >Type of bone lesion on x-ray</td><td align="center" valign="middle" >Bone condensation</td><td align="center" valign="middle" >Bone lysis</td><td align="center" valign="middle" >Bone lysis</td><td align="center" valign="middle" >Bone lysis</td><td align="center" valign="middle" >Bone Lysis (n = 2) Bone Condensation (n = 2)</td><td align="center" valign="middle" >Bone lysis</td></tr></tbody></table></table-wrap><p>- The occurrence of metastases at a late age [<xref ref-type="bibr" rid="scirp.96927-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref9">9</xref>]. The youngest patient in our study was 26 years old; it was an already known cervical cancer, with bone metastases at the pelvis.</p><p>- The male predominance [<xref ref-type="bibr" rid="scirp.96927-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref4">4</xref>].</p><p>- The bone pain remains the main symptom [<xref ref-type="bibr" rid="scirp.96927-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref7">7</xref>].</p><p>- The lumbar spine is the most regular seat of pain [<xref ref-type="bibr" rid="scirp.96927-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref9">9</xref>]. The bone marrow, site of hematopoiesis, is rich in growth factors that could be used by tumor cells [<xref ref-type="bibr" rid="scirp.96927-ref2">2</xref>].</p><p>In our study, bone metastases were revealed in the vast majority of cases (92.75%); same observation with Daboiko [<xref ref-type="bibr" rid="scirp.96927-ref4">4</xref>] (78.6%). Primary cancer was known only in 5 patients.</p><p>A known history of a primary tumor makes it easy to diagnose and reduce the diagnosis delay. Thus, any patient with a known history of neoplasia must be suspected of metastatic spread while facing bone pain [<xref ref-type="bibr" rid="scirp.96927-ref2">2</xref>].</p><p>The diagnosis of bone metastasis is based on imaging and histology [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>].</p><p>The characterization of metastatic bone lesions is a key issue of the patient management. The diagnosis of bone metastasis is evoked on standard X-ray (good specificity), showing lytic, mixed or condensing lesions [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>]. M R I. is the gold standard for spine exploration; it can be used to detect spinal metastasis, to have access on tumor extension, to see the level of spinal cord compression and highlight multiple lesions [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>].</p><p>In our study; we noted a predominance of bone condensation seen on x-ray; this could be explained by the male predominance of our sample and the high incidence of prostate cancer (50%). Indeed, the prostate cancer’s cells mostly stimulate osteoblasts cells (bone formation), leading to bone condensation seen on radiographic imaging [<xref ref-type="bibr" rid="scirp.96927-ref2">2</xref>].</p><p>Our results are different from those of Kouakou [<xref ref-type="bibr" rid="scirp.96927-ref3">3</xref>] and Daboiko [<xref ref-type="bibr" rid="scirp.96927-ref4">4</xref>] who found a predominance of osteolytic forms respectively 59.5% and 69.2% of cases (studies also performed in our rheumatology department). In these two previous studies; prostate cancer was also the first etiology of bone metastases, but the lesions seen on x-ray were predominantly osteolytic.</p><p>Percutaneous bone biopsy under radiological control is a reliable technique with a reliability index greater than 90% [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref10">10</xref>].</p><p>There are two advantages of these bone biopsies:</p><p>- Firstly to confirm the malignancy of bone involvement;</p><p>- Secondly to identify the primary cancer.</p><p>Indeed, in the study of Destombe [<xref ref-type="bibr" rid="scirp.96927-ref11">11</xref>], in France, bone biopsies lead to provide an etiology or at least histological diagnosis in 95% of cases.</p><p>Concerning investigations for the primary tumor in our study; the data from anamnesis, physical examination (digital rectal examination in men and breast palpation in women) and imaging, particularly radiographic (chest x-ray), have been used for the diagnosis of the primary tumor (82.5%).</p><p>Indeed, the contribution of clinical examination is capital; it requires a careful interrogation, with an investigation on personal and family medical history, a complete clinical examination in particular of the skin, the breasts, the lymph nodes areas, the thyroid, the genital and rectal digital examination and testicles examination [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>]. An abnormality discovered leads to perform further investigations. Thus, the ultrasound permitted to give an orientation towards an etiological diagnosis and to limit expensive investigations in our study.</p><p>Although the organ biopsy is useful for the certainty diagnosis, histological examination was performed only in 14 patients in our study. Histology remains the most appropriate examination for the diagnosis of primary cancer of bone metastases. The main limitation of this study which is the absence of histology for all patients.</p><p>In our daily practice, performing histologic examination comes up with several obstacles related to technical difficulties (no availability of sampling equipment, of special stains especially immunohistochemical examination, also the cost of biopsy samples and histologic examination).</p><p>Prostate cancer was the most common primary cancer found in the 3 studies conducted in the Rheumatology Department of the Cocody’s UTH (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>As in the literature [<xref ref-type="bibr" rid="scirp.96927-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref12">12</xref>] ; the most osteophilic cancers remain, the prostate, the lung, the breast, the thyroid and the kidney.</p><p>These tumors (breast, kidney, prostate) spread preferentially in the bone marrow, as if this microenvironment constituted a “soil” favorable to the growth of these tumor cells [<xref ref-type="bibr" rid="scirp.96927-ref2">2</xref>].</p><p>Oniankitan in Togo [<xref ref-type="bibr" rid="scirp.96927-ref7">7</xref>], noted over a period of 17 years, a clear predominance of bone metastases related to prostatic cancers compared to those of breast and cervical cancer.</p><p>In Tubiana [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>] and Conroy studies [<xref ref-type="bibr" rid="scirp.96927-ref12">12</xref>], breast cancer was the most predominant. In Lille, Vandecandelaere and al [<xref ref-type="bibr" rid="scirp.96927-ref13">13</xref>] showed a predominance of lungs cancers compared to prostate and breast cancers.</p><p>If the primary tumor site is not obvious, a thoraco-abdominopelvic CT SCAN may be required to look for a primary tumor or other secondary lesions [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref15">15</xref>].</p><p>The chest x-ray should be systematic because the pulmonary origin of these inaugural bone metastases is very common [<xref ref-type="bibr" rid="scirp.96927-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.96927-ref16">16</xref>].</p><p>The positron emission tomography (PET) with 18-fluorodeoxyglucose coupled to the scanner (PET SCAN) has a high sensitivity that allows the detection of many tumor that have escaped other investigations. Its use is becoming more and more common in oncology practice in devolving countries [<xref ref-type="bibr" rid="scirp.96927-ref1">1</xref>].</p></sec><sec id="s5"><title>5. Conclusion</title><p>Bone metastases mainly affect adults after 50 years of age with male predominance. The circumstances of discovery are in most cases inflammatory rachialgia. The most common primary cancers are: prostate, lung or breast.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Gban&#233;, M., Soglo, J.C., Diomand&#233;, M., Kengni, G.L., Ouattara, B., Kouassi, J.M.D., Kpami, Y.N.C., Coulibaly, Y. and Eti, E. (2020) Etiologies of Bone Metastases at the Rheumatology Department (UTH) of Abidjan. Open Journal of Rheumatology and Autoimmune Diseases, 10, 1-7. https://doi.org/10.4236/ojra.2020.101001</p></sec></body><back><ref-list><title>References</title><ref id="scirp.96927-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Tubiana-Hulin, M., et al. (2008) Stratégie de prise en charge des métastases osseuses révélatrices. Revue du Rhumatisme, 75, 332-338.</mixed-citation></ref><ref id="scirp.96927-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Pointillart, V., Fabre, T. and Palussière, J. (2003) Métastases osseuses. EMC 14-798, 1-9.</mixed-citation></ref><ref id="scirp.96927-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kouakoué</surname><given-names> N.M. </given-names></name>,<etal>et al</etal>. (<year>1994</year>)<article-title>Métastases osseuses en milieu hospitalier Ivoirien</article-title><source> Rhumatologie</source><volume> 46</volume>,<fpage> 243</fpage>-<lpage>245</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.96927-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Daboiko, J.C., Eti, E., Yoboué, K., Ouédraogo, D., Ouali, B., Ouattara, B., Gbané, M., Kouakou, N. and Zué, M. (2002) Cancer secondaire des os en rhumatologie: Huit ans d’expérience. Afrique biomédicale, 7, 27-33.</mixed-citation></ref><ref id="scirp.96927-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Konan, P.G., Gowe, E.E., Dekou, A.H., Fofana, A., Vodi, C.C., Kramo, N.F., Ouegnin, G.A. and Manzan, K. (2015) Cancer métastatique de la prostate dans le service d’urologie du CHU de Cocody. Uro’Andro, 1, 172-176.</mixed-citation></ref><ref id="scirp.96927-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bileckot, R., Miakoundoba, R. and Nstiba, H. (2005) Métastases osseuses: Etude comparative de deux séries à Brazzaville. Revue du Rhumatisme, 72, 1120-1121.</mixed-citation></ref><ref id="scirp.96927-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Oniankitan, O., Houzou, P., Kakpovi, K., et al. (2009) Profil des affections rhumatismales observées à Lomé. Guinée Médicale; 66, 46-53.</mixed-citation></ref><ref id="scirp.96927-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wendling, D., Raguin, J.M. and Guidet, M. (1988) Diagnostic des métastases osseuses en milieu rhumatologique: A propos d’une série de 175 cas. Semaine des h&amp;#244;pitaux de Paris, 64, 2079-2085</mixed-citation></ref><ref id="scirp.96927-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Cayla, J. and Kaddem, S. (1986) Métastases osseuses d’origine inconnue: A propos de 63 cas. Rhumatologie, 38, 241-251.</mixed-citation></ref><ref id="scirp.96927-ref10"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Debiais</surname><given-names> F. </given-names></name>,<etal>et al</etal>. (<year>2015</year>)<article-title>Données épidémiologiques et cliniques des métastases osseuses</article-title><source> Oncologie</source><volume> 17</volume>,<fpage> 63</fpage>-<lpage>68</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.96927-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Destombe, C., Botton, E., Le Gal, G., et al. (2007) Investigations for Bone Metastasis from an Unknown Primary. Joint Bone Spine, 74, 85-89.</mixed-citation></ref><ref id="scirp.96927-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Conroy, T. and Malissard, L. (1988) Natural History and Development of Bone Metastasis. A Propos of 429 Cases. Bulletin du Cancer, 75, 845-857.</mixed-citation></ref><ref id="scirp.96927-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Vandecandelaere, M., Flipo, R.-M., Cortet, B., Catanzariti, L., Dusquenoy, B. and Delcambre, B. (2004) Métastases osseuses révélatrices: étude comparative à 30 ans d’intervalle. Revue du Rhumatisme, 71, 390-396.</mixed-citation></ref><ref id="scirp.96927-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Alberini, J.L., Belhocine, T., Hustinx, R., et al. (2003) Whole-Body Positron Emission Tomography Using Fluorodeoxyglucose in Patients with Metastases of Unknown Primary Tumours (CUP Syndrome). Nuclear Medicine Communications, 24, 1081-1086.</mixed-citation></ref><ref id="scirp.96927-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Demir, H., Berk, F., Raderer, M., et al. (2004) The Role of Nuclear Medicine in the Diagnosis of Cancer. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 48, 164-173.</mixed-citation></ref><ref id="scirp.96927-ref16"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hillen</surname><given-names> H.F. </given-names></name>,<etal>et al</etal>. (<year>2000</year>)<article-title>Unknown Primary Tumours</article-title><source> Postgraduate Medical Journal</source><volume> 76</volume>,<fpage> 690</fpage>-<lpage>693</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref></ref-list></back></article>